PROTHENA CORP PUBLIC LTD CO PRTA

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Prothena Corporation plc ("Prothena" or the "Company") is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases.

Fueled by its deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. The Company's pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying its proprietary CYTOPE® technology to target a broad spectrum of intracellular disease pathways in the brain and periphery.

Last close 8.20 2026-10-23
Market cap $421.0M 2026-06-30 share count
52-week range 7.73 - 11.80

Valuation FY2025 figures against the last close

P/S43.5x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-4.53

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $9.7M$135.2M$91.4M$53.9M$200.6M$853.0K$814.0K$955.0K$27.5M$1.1M
R&D $134.9M$222.5M$220.6M$135.6M$82.3M$74.9M$50.8M$101.2M$134.5M$119.5M
SG&A $59.4M$67.2M$61.8M$49.9M$46.3M$38.7M$35.7M$42.5M$48.2M$41.1M
Total operating expenses $224.3M$289.7M$282.4M$185.5M$128.6M$113.6M$86.5M$159.8M$182.8M$160.6M
Operating income -$214.6M-$154.6M-$191.0M-$131.6M$72.0M-$112.7M-$85.7M-$158.9M-$155.3M-$159.5M
Interest expense $14.1M$25.8M$31.0M$6.3M$42.0K$1.4M$8.2M$2.7M$142.0K$556.0K
Pre-tax income -$200.8M-$128.9M-$160.5M-$125.6M$71.9M-$111.4M-$77.3M-$156.1M-$157.6M-$159.0M
Income tax $43.3M$6.6M$13.5M$8.7M$4.9M$283.0K$379.0K$470.0K$4.4M$1.1M
Net income -$244.1M-$122.3M-$147.0M-$116.9M$67.0M-$111.1M-$77.7M-$155.6M-$153.2M-$160.1M
EPS, basic -4.53-2.27-2.76-2.471.51-2.78-1.95———
EPS, diluted -4.53-2.27-2.76-2.471.38-2.78-1.95-3.93-4.07-4.66
Shares, diluted (wtd. avg.) 53.8M53.8M53.2M47.4M48.5M39.9M39.9M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $307.5M$471.4M$618.8M$712.6M$580.4M$298.1M$378.4M$431.7M$421.7M$391.0M
Receivables —$0$5.2M$0$0$15.0K$68.0K$2.0K$240.0K$178.0K
Total current assets $315.2M$485.4M$639.3M$719.1M$584.8M$299.3M$378.4M$431.4M$426.3M$391.4M
Property, plant and equipment $2.1M$3.1M$3.8M$1.7M$2.0M$2.6M$3.9M$52.8M$55.0M$56.5M
Total assets $326.8M$547.1M$696.4M$758.0M$609.4M$333.0M$419.3M$498.8M$496.3M$460.0M
Accounts payable $5.9M$7.8M$25.4M$9.3M$3.7M$4.1M$1.2M$1.5M$13.6M$13.1M
Total current liabilities $40.8M$48.5M$56.9M$50.1M$33.5M$25.8M$17.7M$14.9M$37.4M$41.1M
Total liabilities $46.3M$60.2M$135.0M$136.0M$143.3M$149.0M$146.3M$175.8M$89.1M$94.6M
Retained earnings -$1.35B-$1.10B-$980.0M-$833.0M-$716.1M-$783.0M-$671.9M-$598.0M-$442.4M-$289.2M
Total equity $280.5M$486.9M$561.4M$622.0M$466.0M$184.0M$272.9M$323.0M$407.2M$365.4M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$163.6M-$150.1M-$133.9M-$108.8M$92.6M-$80.4M-$53.0M-$28.3M-$131.2M-$116.2M
Depreciation and amortisation $895.0K$893.0K$928.0K$744.0K$1.1M$1.5M$1.6M$3.2M$3.1M$2.4M
Stock-based compensation $37.6M$46.0M$40.9M$31.3M$24.7M$22.0M$23.6M$27.0M$26.8M$24.9M
Investing cash flow -$138.0K-$298.0K-$2.8M-$464.0K-$575.0K-$196.0K-$547.0K-$1.7M-$3.5M-$16.6M
Financing cash flow -$139.0K$1.6M$45.1M$241.5M$190.3M$215.0K$228.0K$40.0M$165.4M$153.3M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001559053-26-000008.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -400M -200M 0 200M 400M Revenue, FY2016: 1.1M Net income, FY2016: -160.1M Revenue, FY2017: 27.5M Net income, FY2017: -153.2M Revenue, FY2018: 955K Net income, FY2018: -155.6M Revenue, FY2019: 814K Net income, FY2019: -77.7M Revenue, FY2020: 853K Net income, FY2020: -111.1M Revenue, FY2021: 200.6M Net income, FY2021: 67M Revenue, FY2022: 53.9M Net income, FY2022: -116.9M Revenue, FY2023: 91.4M Net income, FY2023: -147M Revenue, FY2024: 135.2M Net income, FY2024: -122.3M Revenue, FY2025: 9.7M Net income, FY2025: -244.1M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $1.1M $27.5M $955.0K $814.0K $853.0K $200.6M $53.9M $91.4M $135.2M $9.7M
Gross profit — — — — — — — — — —
Net income -$160.1M -$153.2M -$155.6M -$77.7M -$111.1M $67.0M -$116.9M -$147.0M -$122.3M -$244.1M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote Item 5.07
  • Results announced Item 2.02
  • Other event Item 8.01
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%